Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Infographic – US Public Supports Govt Science Spending

Chart: U.S. trust in science

Most Americans believe the U.S. should be the world leader in scientific achievement, and support continued U.S. government investments in science. . . . → Read More: Infographic – US Public Supports Govt Science Spending

AI Analytics Boost Breast Cancer Assessment Diversity

Breast cancer cell

A genomic analytics company says an ethnicity algorithm added to a personal health questionnaire improves risk assessments for breast cancer across all populations. . . . → Read More: AI Analytics Boost Breast Cancer Assessment Diversity

Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Breast tumor microenvironment

Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Trial Shows Antibody Neutralizes, Reduces HIV Virus

T-cell infected by HIV

Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease. . . . → Read More: Trial Shows Antibody Neutralizes, Reduces HIV Virus

Immunotherapy Start-Up Launches Collaboration, Raises $65M

T-cells and cancer cells

A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M

Grant Funds Regenerative Gel for Treating Skin Ulcers

Antoni Ribas

A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers

Infographic – Q3 Digital Health Venture Funds Slide

Digital health funds Q3 2022

Venture funding for start-ups worldwide applying digital technologies to health care continued to fall in the third quarter of 2022, both in deals and dollars invested. . . . → Read More: Infographic – Q3 Digital Health Venture Funds Slide

New Funds Awarded for Rapid Infection Diagnostics

Hospital room

A developer of faster infection diagnostics is receiving another $8.2 million from an international group supporting solutions to antibiotic resistant microbes. . . . → Read More: New Funds Awarded for Rapid Infection Diagnostics

Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised

Global Covid-19

A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised